New data showed that patients who were treated with osimertinib have higher progression-free survival (PFS) compared to those who accepted first-line treatment (gefitinib or erlotinib), so osimertinib was elevated to first-line therapy for EGFR-mutant NSCLC.[38] The treatment of EGFR-mutant NSCLC has changed dramatically in the past few years.[39]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.